News

Company to Evaluate Orphan Diseases as Secondary Indications BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 28, 2013) BioAegis Therapeutics announced that the FDA has transferred Orphan Designations for cystic fibrosis and bronchiectasis to the company. The FDA Office of Orphan Products Development (OOPD) provides support and incentives for sponsors to develop products for …

July 28, 2013: FDA Transfers Orphan Drug Designation for Cystic Fibrosis and Bronchiectasis to BioAegis Therapeutics Read More »

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 26, 2013) BioAegis Therapeutics announced today that a patent has been granted in Japan that that covers the diagnostic claims of the therapeutic and diagnostic application. Further Japanese applications for therapeutic claims in inflammation are pending.

Bolognese to Provide Statistical Design of Biomarker-Driven Phase 2b Human Efficacy Study in Severe Community-Aquired Pneumonia BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – June 15, 2013) BioAegis Therapeutics announced today that it has engaged Jim Bolognese, Senior Director of Strategic Consulting at Cytel Inc., a leading firm in the design and conduct of adaptive …

June 15, 2013: BioAegis Therapeutics Engages Jim Bolognese, Senior Director of Strategic Consulting at Cytel Read More »

Supplies to be Used in Forthcoming Human Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – April 15, 2013) BioAegis Therapeutics announced today that it has engaged the Billingham, UK group of Fujifilm Diosynth—a first-tier contract biologics manufacturer, to manufacture clinical-grade supplies of recombinant human plasma gelsolin, the body’s 4th most abundant plasma protein that …

April 15, 2013: BioAegis Therapeutics Engages FujiFilm Diosynth Biotechnlogies to Manufacture Clinical-Grade Supply of Recombinant Human Plasma Gelsolin Read More »

Patent Covers Use of Plasma Gelsolin to Treat Multiple Sclerosis and to Diagnose Neurologic Diseases BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today that broad US patent protection for plasma gelsolin to treat Multiple Sclerosis (MS) and to diagnosis neurological disease. MS affects approximately 400,000 people in the …

March 4, 2013: High-Value US Neurological Patent Issued Read More »

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 1, 2013) BioAegis Therapeutics announced today that it has opened a research laboratory facility at the NJ Commercialization Center of Innovative Technology in North Brunswick, New Jersey.

Plans Phase 2b/3 Trial for Biologic in Prevention of Organ Dysfunction in ICU BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – February 7, 2013) BioAegis Therapeutics announced today that it completed it’s initial $3MM convertible note round to fund the companies operating activites in its effort to commercialize groundbreaking discoveries as to plasma gelsolin’s (pGSN) …

February 7, 2013: BioAegis Therapeutics Completes Initial $3MM Raise Read More »

Advisors Engaged to Advance Biomarker-Driven Clinical Program BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – January 15, 2013) BioAegis Therapeutics announced that it has assembled a Critical Care Clinical Advisory Board comprised of world-recognized, highly experienced key opinion leaders. Initial members are: Derek Angus, M.D., Professor and Chair, Critical Care Medicine and Professor, Medicine and …

January 15, 2013: BioAegis Assembles World-Class Clinical Advisory Board Read More »

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2012) Pursuant to the terms of the agreement with the Brigham and Women’s Hospital previously announced on May 11, 2011, BioAegis Therapeutics elected to exercise its option into an exclusive license to recombinant human plasma gelsolin technology.

BioAegis’ Patent Coverage Expands to Asia Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria and this broad patent filing was recently granted in China. BioAegis is pursuing worldwide patent filings for infectious disease.